Troponin I

In a large hospital population, most of whom did not have an indication for troponin testing, high levels of cardiac troponin were associated with elevated risk for all-cause mortality, researchers reported.

One high-sensitivity cardiac troponin I measurement under the limit of detection — 2 ng/L — may be enough to rule out MI with high sensitivity among patients who present within 12 hours of symptom onset, researchers reported.

The minimum high-sensitivity cardiac troponin I tied to 30-day death after cardiac surgery was found to be significantly greater than what is currently recommended to diagnose periprocedural myocardial injury, researchers reported.

Most pediatric patients with multisystem inflammatory syndrome also had evidence of myocardial injury, but functional recovery was quick with no adverse coronary outcomes, researchers reported.

CV biomarkers that quantify myocardial injury, endothelial dysfunction, microvascular dysfunction and/or hemodynamic stress successfully provided modest discrimination in a noninvasive diagnosis of type 2 MI, researchers reported.

Using a novel saliva-based rapid cardiac troponin I test to diagnose MI was feasible, according to the results of a preliminary study presented at the European Society of Cardiology Congress.

The prevalence of myocardial injury in acute COVID-19 is low, but its presence was significantly associated with worse outcomes, researchers reported.

Abbott announced that a high-sensitivity troponin I blood test used to detect MI has received FDA clearance.

PARIS — Risk stratification thresholds for high-sensitivity cardiac troponin I were able to safely and effectively identify patients with ACS and at least 2 hours of symptoms as low risk regardless of sex and age, according to data from the HiSTORIC trial presented at the European Society of Cardiology Congress.

In older long-distance walkers, troponin I levels above the 99th percentile were associated with higher risk for mortality and CV events.